FILE 01 / GLP-1
Semaglutide: research overview
A mature human evidence file. Strong weight and clinical-event data. Body composition needs a separate reading.
The short version
Semaglutide is a modified version of GLP-1, a gut hormone that helps regulate blood sugar and appetite. It activates the GLP-1 receptor. The signal increases insulin release when glucose is present, reduces excess glucagon, slows stomach emptying, and changes appetite circuits in the brain.
Its human evidence is substantial. Large trials show lower body weight and fewer cardiovascular events in selected populations. Kidney outcomes also improved in people who had type 2 diabetes and chronic kidney disease [2][3][4]. These results make semaglutide the most clinically mature compound on this site.
The functional question is less simple. Weight loss includes fat and lean tissue. A lower scale number does not prove that muscle, strength, or mobility was preserved. Gastrointestinal effects are common, and biliary disease is a recognized concern [5]. The evidence is strong. The outcome being measured still matters.
What it is
Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist and incretin mimetic. Incretins are hormones released after food intake. They help coordinate insulin, glucagon, gastric emptying, and satiety.
The molecule is a modified peptide analogue. Structural changes protect it from rapid enzymatic breakdown and increase binding to albumin in the blood. Those changes extend its circulation far beyond native GLP-1. Different approved products and indications exist, but this page evaluates the shared molecule through the studies in the composed source set. Brand names identify regulated products; they do not imply endorsement.
Semaglutide belongs in metabolic research because its program moved from glucose markers and body weight to hard clinical events. That breadth is unusual. It also makes precision necessary. Evidence from adults with established cardiovascular disease cannot be silently applied to every population. Evidence from chronic kidney disease cannot be reduced to a generic wellness claim.
How it works
Semaglutide activates GLP-1 receptors in several connected systems. In pancreatic beta cells, it supports glucose-dependent insulin secretion. In alpha cells, it suppresses inappropriate glucagon release. In the stomach and through vagal signaling, it slows gastric emptying. In hypothalamic and brainstem circuits, it shifts signals for appetite, satiety, meal termination, and food preference.
The weight effect is driven mainly by lower energy intake. The source mechanism does not describe a primary increase in energy expenditure. That distinction separates semaglutide from research programs built around thermogenesis or exercise mimetics.
The same mechanism helps explain part of the adverse-effect profile. Slower gastric emptying can produce nausea, vomiting, constipation, diarrhea, bloating, reflux, and other gastrointestinal symptoms. The target is metabolically effective, but the digestive tract is part of the target system. Mechanism and tolerability are linked.
What the research shows
The STEP 1 randomized trial studied adults with overweight or obesity without diabetes. Mean body-weight change at week 68 was −14.9% with semaglutide and −2.4% with placebo [4]. This establishes a large average weight effect in that trial population. It does not specify how every kilogram was distributed between fat and lean tissue.
SELECT tested a different outcome. It enrolled 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes. Major adverse cardiovascular events were lower with semaglutide than placebo, with a hazard ratio of 0.80 [3]. FLOW enrolled 3,533 people with type 2 diabetes and chronic kidney disease. Its major kidney composite favored semaglutide, with a hazard ratio of 0.76 [2].
A head-to-head obesity trial provides context rather than a universal ranking. At 72 weeks, mean weight loss was −13.7% with semaglutide and −20.2% with tirzepatide among 751 adults [1]. The comparison shows that semaglutide is not the ceiling for scale-weight change. It says nothing direct about tesamorelin or MOTS-c, which engage different systems and were not part of that trial.
Reported effects, cautions & safety
The following reports are anecdotal, not clinical evidence. Research and patient communities frequently describe quieter appetite signals, reduced cravings, earlier fullness, and weight loss. They also frequently describe nausea and commonly report bowel changes, fatigue, reflux, and unpleasant burping. These reports can show what people notice. They cannot estimate efficacy, frequency, or causation with trial-level reliability.
The clinical literature gives a firmer safety frame. A dedicated review describes gastrointestinal effects as mostly mild to moderate and transient, with nausea reported in roughly one-third of patients; it also identifies increased biliary-disease risk [5]. Pancreatic and thyroid-cancer signals were not resolved because events were uncommon [5].
Rapid weight loss also raises a body-composition concern. Total weight can fall while lean mass falls with it. That does not erase the benefits demonstrated in cardiovascular or kidney trials. It changes the functional reading. Muscle mass, strength, dietary intake, and mobility require direct measurement rather than inference from body weight alone. This page does not provide individual risk assessment or treatment instructions.
Where it fits in metabolic function
Semaglutide is the strongest file here for scale-weight change and major clinical outcomes. It offers direct human evidence for weight, cardiovascular events, and kidney events across defined trial populations [2][3][4].
Its limitation within this hub is equally clear. The headline outcomes do not answer every question about lean tissue, strength, or movement. A functional assessment must track what the scale cannot separate. Semaglutide therefore anchors the clinical-outcomes end of the comparison. Tesamorelin anchors tissue distribution and body composition. MOTS-c anchors early-stage work on muscle and cellular energy signaling.
These positions are descriptive. They are not a recommendation or a claim of interchangeability. The compounds differ in mechanism, regulatory status, evidence maturity, and the populations studied.